Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68001-0682-26 68001-0682 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Dec 1, 2025 In Use
68001-0681-25 68001-0681 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Dec 1, 2025 In Use
68001-0673-06 68001-0673 Abiraterone Acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Oct 16, 2025 In Use
68001-0669-15 68001-0669 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 3, 2026 In Use
68001-0668-19 68001-0668 Aprepitant Aprepitant 125.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 10, 2026 In Use
68001-0667-19 68001-0667 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jan 29, 2026 In Use
68001-0667-01 68001-0667 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 2, 2026 In Use
68001-0666-17 68001-0666 Aprepitant Aprepitant 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 2, 2026 In Use
68001-0666-01 68001-0666 Aprepitant Aprepitant 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jan 29, 2026 In Use
68001-0665-04 68001-0665 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 5, 2025 In Use
68001-0664-04 68001-0664 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 29, 2025 In Use
68001-0663-04 68001-0663 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 1, 2025 In Use
68001-0662-06 68001-0662 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 29, 2025 In Use
68001-0661-06 68001-0661 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct 30, 2025 In Use
68001-0660-06 68001-0660 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 24, 2025 In Use
68001-0656-41 68001-0656 Eribulin Mesylate Eribulin Mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous Oct 8, 2025 In Use
68001-0655-17 68001-0655 ISOTRETINOIN ZENATANE 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec 24, 2025 In Use
68001-0653-17 68001-0653 ISOTRETINOIN ZENATANE 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec 24, 2025 In Use
68001-0652-17 68001-0652 ISOTRETINOIN ZENATANE 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec 30, 2025 In Use
68001-0651-37 68001-0651 Paclitaxel Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous Jul 18, 2025 In Use
68001-0650-38 68001-0650 Leucovorin Calcium Leucovorin Calcium 350.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Aug 15, 2025 In Use
68001-0649-37 68001-0649 Leucovorin Calcium Leucovorin Calcium 200.0 mg/20mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Aug 14, 2025 In Use
68001-0648-36 68001-0648 Leucovorin Calcium Leucovorin Calcium 100.0 mg/10mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Aug 14, 2025 In Use
68001-0644-07 68001-0644 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Apr 22, 2025 In Use
68001-0643-06 68001-0643 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Apr 18, 2025 In Use

Found 12393 results — Export these results